NCT05296603View on ClinicalTrials.gov

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

October 30, 2024

Study Completion Date

December 25, 2025

Conditions
Small Cell Lung Cancer
Interventions
DRUG

IBI-322 Plus Lenvatinib

"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER